Please check your internet connection and try again.
# Pantoprazole
## Overview
Pantoprazole is a proton pump inhibitor (PPI) that decreases acid production in the stomach.
## Primary Indications
* Healing of erosive esophagitis associated with gastroesophageal reflux disease (GERD).
* Reduction of risk of rebleeding from peptic ulcers.
* Treatment of pathological hypersecretory conditions, such as Zollinger-Ellison syndrome.
## Adult Dosing
* **Erosive esophagitis:** 40 mg orally or intravenously once daily for up to 8 weeks. A subsequent 8-week course may be indicated for patients who have not healed.
* **Maintenance of healing of erosive esophagitis:** 40 mg orally once daily.
* **GERD (symptomatic):** 20 mg orally once daily for up to 4 weeks.
* **H. pylori eradication (in combination therapy):** 40 mg orally twice daily for 7-14 days.
* **Pathological hypersecretory conditions:** Starting dose 40 mg orally or intravenously twice daily. Doses may be adjusted upwards based on clinical response. Maximum recommended daily oral dose is 240 mg. Maximum recommended daily IV dose is 80 mg.
## Pediatric Dosing
Dosing in pediatric patients varies significantly by indication and age. Specific recommendations are often based on weight and clinical judgment. Consult pediatric-specific guidelines.
* **Erosive esophagitis (5-16 years):** 20-40 mg orally once daily.
* **Pathological hypersecretory conditions (≥12 years):** 40 mg orally twice daily.
## Dose Adjustments
* **Hepatic Impairment:** Maximum daily dose of 40 mg orally or 40 mg intravenously.
## Contraindications
* Known hypersensitivity to pantoprazole or any component of the formulation.
## Adverse Effects
Common: Headache, diarrhea, nausea, abdominal pain, flatulence, dizziness.
Less common: Rash, urticaria, pruritus, insomnia, fatigue.
Long-term use of PPIs is associated with an increased risk of:
* Fractures (hip, wrist, spine)
* Clostridium difficile infection
* Vitamin B12 deficiency
* Hypomagnesemia
* Rebound acid hypersecretion upon discontinuation.
## Key Drug Interactions
* **Antiretrovirals (e.g., nelfinavir, rilpivirine):** Pantoprazole may decrease their absorption.
* **Methotrexate:** PPIs may increase levels of methotrexate.
* **CYP2C19 and CYP3A4 substrates:** Pantoprazole can inhibit CYP2C19, potentially affecting the metabolism of drugs like clopidogrel.
## Monitoring
* Monitor for clinical response and signs of adverse effects.
* Consider magnesium levels with prolonged therapy (>3 months), especially in patients taking diuretics or digoxin.
* Consider vitamin B12 levels with prolonged therapy (>3 years).
## Clinical Pearls
* Oral pantoprazole should be taken at least 30 minutes before a meal.
* For IV administration, reconstitute and dilute according to manufacturer instructions.
* Discontinuation should ideally be tapered to minimize rebound acid hypersecretion, especially after long-term use.
***
*This information is intended for healthcare professionals and is not a substitute for professional medical advice. Always consult the most current prescribing information and professional resources for definitive guidance. Dosing may vary based on individual patient factors and local protocols.*
